Author Archives: admin


‘I’LL BEAT THIS CANCER AGAIN’

CANCER sufferer Kate Blackhurst is recovering at home after undergoing a revolutionary stem cell transplant to try to beat the disease.

The 20-year-old, picturedright, was offered the treatment on the NHS after being struck down with cancer twice in three years.

The latest treatment saw some of Kate's healthy stem cells frozen by experts at The Queen Elizabeth Hospital, in Birmingham.

She then received chemotherapy five times more powerful than a normal dose to try to kill the cancerous cells as the frozen stem cells were put back in her body during almost four weeks of treatment last month.

myprint-247

Print voucher

Our heavyweight cards have FREE UV silk coating, FREE next day delivery & VAT included. Choose from 1000's of pre-designed templates or upload your own artwork. Orders dispatched within 24hrs.

Terms: Visit our site for more products: Business Cards, Compliment Slips, Letterheads, Leaflets, Postcards, Posters & much more. All items are free next day delivery. http://www.myprint-247.co.uk

Contact: 01858 468192

Valid until: Sunday, June 16 2013

Here is the original post:
'I'LL BEAT THIS CANCER AGAIN'

Newly discovered cell shows promise for liver regeneration

Washington, June 10 (ANI): Liver transplantation is the mainstay of treatment for patients with end-stage liver disease, but a new research from the Icahn School of Medicine at Mount Sinai has suggested that it may one day become possible to regenerate a liver using cell therapy in patients with liver disease.

Investigators discovered that a human embryonic stem cell can be differentiated into a previously unknown liver progenitor cell, an early offspring of a stem cell, and produce mature and functional liver cells.

"The discovery of the novel progenitor represents a fundamental advance in this field and potentially to the liver regeneration field using cell therapy," said the study's senior author, Valerie Gouon-Evans, PharmD, PhD, Assistant Professor, in the Department of Developmental and Regenerative Biology, Black Family Stem Cell Institute, at the Icahn School of Medicine at Mount Sinai.

"Until now, liver transplantation has been the most successful treatment for people with liver failure, but we have a drastic shortage of organs. This discovery may help circumvent that problem,"

In conjunction with the laboratory of Matthew J. Evans, PhD, from the Department of Microbiology at Icahn School of Medicine at Mount Sinai, investigators demonstrated the functionality of the liver cells generated from the progenitors, as the liver cells can be infected by the hepatitis C virus, a property restricted to liver cells exclusively.

A critical discovery in this research was finding that the novel progenitor has a receptor protein on its cell surface called KDR, or vascular endothelial growth factor receptor 2, which until now, was thought to be restricted to endothelial cells that form vessels, the progenitors for endothelial cells and the progenitors blood cells.

The research team showed that activation of KDR on these novel liver progenitors differentiates them into mature liver cells. Additionally, work in a mouse model revealed similar cells, indicating that the progenitors are conserved from mouse to human, and therefore, they must be "important cells with promising potential for cell therapy in treating liver disease," explained Dr. Gouon-Evans.

Next, the research team will examine specifically whether these liver cells obtained from human embryonic stem cells in a dish help repair injured livers in preclinical animal models of liver disease.

The study was published in the journal Cell Stem Cell. (ANI)

Read the original:
Newly discovered cell shows promise for liver regeneration

BrainStorm Treats 8th Patient in Phase IIa Trial; Completes Enrollment of Final 4 Patients

NEW YORK, NY and PETACH TIKVAH, ISRAEL--(Marketwired - Jun 10, 2013) - BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has successfully treated the eighth patient in its ongoing Phase IIa ALS clinical trial at the Hadassah Medical Center in Jerusalem, Israel, thus completing treatment of the second of three cohorts. Enrollment of the final group of four patients has also been completed, and the company expects to conclude treatment of these patients by the end of the third quarter of this year.

In this Phase IIa dose-escalating trial, currently underway at Hadassah under the direction of Principal Investigator Professor Dimitrios Karussis, 12 ALS patients are receiving combined intramuscular (IM) and intrathecal (IT) administration of NurOwn cells, in three cohorts, with increasing doses. The study participants will be monitored for six months following transplantation.

About BrainStorm Cell Therapeutics, Inc. BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the company's website at http://www.brainstorm-cell.com.

Safe Harbor Statement - Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may," "should," "would," "could," "will," "expect," "likely," "believe," "plan," "estimate," "predict," "potential," and similar terms and phrases are intended to identify these forward-looking statements.The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov.These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements.The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

View post:
BrainStorm Treats 8th Patient in Phase IIa Trial; Completes Enrollment of Final 4 Patients

The Science of Mesenchymal Stem Cells and Regenerative Medicine – Arnold Caplan PhD (Part 1) – Video


The Science of Mesenchymal Stem Cells and Regenerative Medicine - Arnold Caplan PhD (Part 1)
Professor Arnold Caplan of Case Western Reserve University is widely regarded as "The Father of the Mesenchymal Stem Cell". This lecture is a "must see" for ...

By: http://www.cellmedicine.com

Go here to see the original:
The Science of Mesenchymal Stem Cells and Regenerative Medicine - Arnold Caplan PhD (Part 1) - Video

Lewis County man hopes for stem cell therapy

VANCEBURG | A Lewis County man is working his way toward stem cell therapy in an attempt to help him walk again.

Jennifer Richardson, a long-time friend of Anthony Schumacher, said Schumacher was involved in an accident in December 2012, which left him paralyzed.

According to Richardson, Schumacher was in a comma for a few days and has no memory of the accident.

"He was going to work when his tire blew out and he wrecked the car," Richardson said. "He was in a coma for days and when he woke up he was paralyzed from the belly button down and couldn't remember anything."

Tammy Moore, Schumacher's mother, said he keeps a positive attitude about his situation.

"He's a happy person," she said. "He works out everyday and tries to learn new things about his situation and the procedure."

Moore said she would like to see Schumacher get the therapy.

"I don't know a lot about it. I'm still learning about it," she said. "But, from what I've seen, it's a good thing that can help him get at least some of the feeling back, if not all. I want to see him get it, if it can help."

Schumacher said he looks forward to the possibility of the procedure, too.

"I'm hopeful," he said. "I want to get it done. I've been trying to do my research and I would like to do this."

Go here to read the rest:
Lewis County man hopes for stem cell therapy

$150,000 donation to fund stem cell research

A Newport Beach nonprofit donated $150,000 toward stem cell research that could slow or reverse heart damage in patients, including those with a specific muscular dystrophy condition, the organization announced last week.

Coalition Duchenne gave the money to a Cedars-Sinai Heart Institute team developing a treatment that could help treat Duchenne muscular dystrophy patients who develop heart disease, according to a news release from the coalition.

Boys with Duchenne are born with damage to their hearts that worsens over time, according to Dr. Ron Victor, associate director of the Cedars-Sinai Heart Institute.

"If we can use stem cells to slow or stop heart damage, it could help stall progression of the disease," he said in a prepared statement.

The institute's experimental treatment involves removing a raisin-size piece of heart muscle that is used to grow the stem cells.

Researchers have seen an average 50% reduction in muscle damage following a heart attack when those cells are injected back into the patient, according to the release.

"Each year, 20,000 boys are born with Duchenne," said Catherine Jayasuriya, who founded Coalition Duchenne in 2010 after her son was diagnosed with cardiomyopathy associated with the disease. "Many do not live into their 20s and we lose many to cardiac issues. We need to focus on changing the course of the disease. We hope that working with cardiac stem cells is one way we will eventually change that outcome."

Jeremiah Dobruck

Twitter: @jeremiahdobruck

Visit link:
$150,000 donation to fund stem cell research